Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Express Scripts
Medtronic
Johnson and Johnson
Mallinckrodt
US Army

Generated: August 20, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,722,865

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,722,865
Title:Isolated genomic polynucleotide fragments from the p15 region of isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4)
Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human and tumor suppressing subtransferable candidate 4 (TSSC4) and methods of use.
Inventor(s): Ryan; James (Augusta, GA)
Assignee: Kyoger, LLC (N/A)
Application Number:13/244,468
Patent Claims:1. An isolated polynucleotide selected from the group consisting of (a) an isolated polynucleotide consisting of a nucleic acid sequence which is at least 99% identical to the polynucleotide shown in SEQ ID NO:12; (b) a polynucleotide fragment of (a) comprising at least nucleotides 13982-14971 of SEQ ID NO:12, wherein (a)-(b) encode a polypeptide which is at least 99% identical to SEQ ID NO:6 and has human tumor suppressing subtransferable candidate 4 (TSSC4) activity or (c): a reverse strand of the polynucleotides of (a) or (b), wherein the isolated polynucleotide is modified.

2. A nucleic acid construct comprising the polynucleotide of claim 1.

3. An expression vector comprising the polynucleotide of claim 1.

4. A recombinant host cell comprising the polynucleotide of claim 1.

5. A method for obtaining human tumor suppressing subtransferable candidate 4 (TSSC4) comprising: (a) culturing the recombinant host cell of claim 4 under conditions that provide for the obtaining of human tumor suppressing subtransferable candidate 4 (TSSC4) and (b) recovering said human tumor suppressing subtransferable candidate 4 (TSSC4).

6. An isolated polynucleotide at least 50 nucleotides in length identical to a region of SEQ ID NO:12, said region selected from the group consisting of a 5'-noncoding region, a 3'-non-coding region and a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12 or reverse strand of said polynucleotide, wherein the isolated polynucleotide is modified.

7. The isolated polynucleotide of claim 6, wherein said 5'-noncoding region consists of nucleotides 1-13981 of SEQ ID NO:12 and said 3'-non-coding region consists of nucleotides 14968-14972 of SEQ ID NO:12.

8. A composition comprising the polynucleotide of claim 1 and a carrier or diluent.

9. A composition comprising the polynucleotide of claim 6 and a carrier or diluent.

10. A kit comprising the polynucleotide of claim 1.

11. A kit comprising the polynucleotide of claim 6.

12. A method for preparing an antibody specific to human tumor suppressing subtransferable candidate 4 (TSSC4) comprising: (a) obtaining a polypeptide according to the method of claim 5; (b) optionally conjugating said polypeptide to a carrier protein; (c) immunizing a host animal with said polypeptide or polypeptide-carrier protein conjugate of step (b) with an adjuvant and (d) obtaining antibody from said immunized host animal.

13. A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of claim 1 effective to prevent, treat or ameliorate said medical condition.

14. A method for preventing, treating or ameliorating a medical condition, comprising administering to a subject an amount of the composition of claim 6 effective to prevent, treat or ameliorate said medical condition.

15. A method of identifying variants of SEQ ID NO:12 or its complementary sequence comprising (a) isolating genomic DNA from a subject and (b) determining the presence or absence of a variant in said genomic DNA using the polynucleotide of claim 6.

16. A method for detecting the presence or absence of a nucleic acid sequence of SEQ ID NO:12 or its complementary sequence in a sample, said method comprising contacting the sample with the polynucleotide of claim 6.

17. A method of detecting the presence or absence of a variant of human tumor suppressing subtransferable candidate 4 (TSSC4) in a sample using the polynucleotide of claim 1.

18. A method of detecting the presence or absence of a nucleotide variant of SEQ ID NO:12, or its complementary sequence comprising: (a) isolating genomic DNA from a subject, and (b) determining the presence or absence of a nucleotide sequence variation in said genomic DNA by comparing the nucleotide acid sequence of SEQ ID NO:12 with the nucleotide sequence of the isolated genomic DNA of (a) and establishing if and where a difference occurs between the two nucleic acid sequences thereby identifying a nucleotide sequence variant of SEQ ID NO:12, or its complementary sequence.

19. A method for obtaining the polynucleotide of claim 1 comprising (a) isolating genomic polynucleotide from a subject; (b) providing primers, probes and optionally polymerase, wherein said primers or probes ace at least 50 nucleotides in length identical to a region of SEQ ID NO: 12, said region selected from the group consisting of a 5'-noncoding region, an intron, 3'-non-coding region and a contiguous coding and non-coding, nucleic acid sequence region of SEQ ID NO: 12 reverse strand of said regions and (c) incubating (a) and (b) under conditions promoting the isolation of said polynucleotide.

20. A method for obtaining the polynucleotide of claim 6 comprising (a) isolating genomic polynucleotide from a subject; (b) providing primers, probes and optionally polymerase, wherein said primers or probes are at least 50 nucleotides in length identical to a region of SEQ ID NO: 12 said region selected from the group consisting of a 5'-noncoding region, an intron, a 3'-non-coding region and contiguous coding and non-coding sequence region of SEQ ID NO:12, or reverse strand of said regions and (c) incubating (a) and (b) under conditions promoting the isolation of said polynucleotide.

21. The polynucleotide according to claim 1, wherein said polynucleotide is DNA or RNA.

22. An isolated polynucleotide consisting of a 5'-noncoding region, a 3'-non-coding region or a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12, or reverse strand of said polynucleotide, wherein the 5'-noncoding region consists of nucleotides 14969-15540 of SEQ ID NO:12 and the 3'-noncoding region consists of nucleotides 1-13981 of SEQ ID NO:12, wherein the isolated polynucleotide is modified.

23. An isolated polynucleotide fragment of the isolated polynucleotide of claim 22, wherein said fragment is at least 500 nucleotides in length.

24. The method according to claim 19, wherein said polynucleotide is DNA or RNA.

25. The method according to claim 20, wherein said polynucleotide is DNA or RNA.

26. The polynucleotide of claim 6, wherein said polynucleotide is DNA or RNA.

27. The polynucleotide of claim 22, wherein said polynucleotide is DNA or RNA.

28. A kit comprising the polynucleotide of claim 22.

29. A nucleic acid construct comprising an isolated polynucleotide selected from the group consisting of (a) an isolated polynucleotide consisting of a nucleic acid sequence which is at least 99% identical to the polynucleotide shown in SEQ ID NO:12; (b) a polynucleotide fragment of (a) comprising at least nucleotides 13982-14971 of SEQ ID NO:12, wherein (a)-(b) encode a polypeptide which is at least 99% identical to SEQ ID NO:6 and has human tumor suppressing subtransferable candidate 4 (TSSC4) activity or (c) a reverse strand of the polynucleotides of (a) or (b).

30. A recombinant expression vector comprising the nucleic acid construct of claim 29.

31. A recombinant host cell comprising the nucleic acid construct of claim 29.

32. A kit comprising at least one of: (i) an isolated polynucleotide selected from the group consisting of (a) an isolated polynucleotide consisting of a nucleic acid sequence which is at least 99% identical to the polynucleotide shown in SEQ ID NO:12; (b) a polynucleotide fragment of (a) comprising at least nucleotides 13982-14971 of SEQ ID NO:12, wherein (a)-(b) encode a polypeptide which is at least 99% identical to SEQ ID NO:6 and has human tumor suppressing subtransferable candidate 4 (TSSC4) activity or (c) a reverse strand of the polynucleotides of (a) or (b), wherein said isolated polynucleotide is optionally labeled with a detectable substance, (ii) an isolated polynucleotide at least 50 nucleotides in length identical to a region of SEQ ID NO:12, said region selected from the group consisting of a 5'-non-coding region, a 3'-non-coding region and a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12 or reverse strand of said polynucleotide, wherein said isolated polynucleotide is optionally labeled with a detectable substance, or (iii) an isolated polynucleotide consisting of a 5'-non-coding region, a 3'-non-coding region or a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:12 or reverse strand of said polynucleotide, wherein the 5'-non-coding region consists of nucleotides 14969-15540 of SEQ ID NO:12 and the 3'-noncoding region consists of nucleotides 1-13981 of SEQ ID NO:12, wherein said isolated polynucleotide is optionally labeled with a detectable substance.

Details for Patent 8,722,865

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Kyoger, LLC (N/A) 2020-10-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Kyoger, LLC (N/A) 2020-10-31 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Kyoger, LLC (N/A) 2020-10-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 8,722,865

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 02061085 Aug 08, 2002
World Intellectual Property Organization (WIPO) 02061085 Dec 11, 2003
United States of America 2003039982 Feb 27, 2003
United States of America 2012010268 Jan 12, 2012
United States of America 2012010269 Jan 12, 2012
United States of America 2012010270 Jan 12, 2012
>Country >Patent Number >Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Julphar
AstraZeneca
Teva
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.